Skip to main content
Erschienen in: Endocrine 2/2017

08.09.2017 | Original Article

Increased mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: a 13-year retrospective study from one center

verfasst von: Jekaterina Patrova, Magnus Kjellman, Hans Wahrenberg, Henrik Falhammar

Erschienen in: Endocrine | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To compare long-term outcomes in patients with adrenal incidentalomas (AIs) with the response to a 1 mg overnight dexamethasone suppression test (DST).

Methods

Consecutive patients with “non-functional” AIs (n = 365) were examined. Patients with overt hormone excess, adrenocortical cancer and known malignancy had been excluded. Patients were classified to normal cortisol secretion group (n = 204, DST ≤ 50 nmol/l), possible autonomous cortisol secretion group (n = 128, DST 51–138 nmol/l) and autonomous cortisol secretion group (n = 33, DST ≥ 138 nmol/l).

Results

Thirty-seven patients (10.1%) deceased during the follow-up period (5.2 ± 2.3 years): 16(7.8%) in the non-secreting group (time from diagnosis to death: 3.9 ± 2.9 years), 15 in the possible autonomous cortisol secretion group (11.7%, 3.2 ± 1.8 years) and 6 in the autonomous cortisol secretion group (18.2%, 2.3 ± 1.5 years), respectively (P = 0.019). Multivariate analysis only found significant association with age and the tumour size but if cortisol levels post-DST were analysed as a continuous variable it was significant as well. All deaths in autonomous cortisol secretion group were due to cancer not related to adrenal glands. Hypertension, cardiovascular disease and medications were more common in the possible and autonomous cortisol secretion group, especially in the former. More bilateral AIs and larger AI size were found in the two latter groups.

Conclusions

Patients with autonomous cortisol secretion had higher mortality than those with non-functioning AIs though cortisol levels post-DST as a continuous variable, age and tumour size were better predictor of mortality. Cardiovascular disease and osteoporosis medication seemed more prevalent in the possible and autonomous cortisol secretion groups, especially in the former.
Literatur
1.
Zurück zum Zitat G. Di Dalmazi, R. Pasquali, F. Beuschlein, M. Reincke, Subclinical hypercortisolism: a state, a syndrome, or a disease? Eur. J. Endocrinol. 173(4), 61–71 (2015)CrossRef G. Di Dalmazi, R. Pasquali, F. Beuschlein, M. Reincke, Subclinical hypercortisolism: a state, a syndrome, or a disease? Eur. J. Endocrinol. 173(4), 61–71 (2015)CrossRef
2.
Zurück zum Zitat N. I. H. Consensus and S. Statements, NIH state-of-the-science statement on management of the clinically inapparent adrenal mass (‘incidentaloma’). NIH Consens State Sci. Statements 19(2), 1–25 (2002) N. I. H. Consensus and S. Statements, NIH state-of-the-science statement on management of the clinically inapparent adrenal mass (‘incidentaloma’). NIH Consens State Sci. Statements 19(2), 1–25 (2002)
3.
Zurück zum Zitat M. Fassnacht, W. Arlt, I. Bancos, I. Dralle, Management of adrenal incidentalomas: European society of endocrinology clinical practice guideline in collaboration with the European network for the study of adrenal tumors. Eur. J. Endocrinol. 175(2), 1–34 (2016)CrossRef M. Fassnacht, W. Arlt, I. Bancos, I. Dralle, Management of adrenal incidentalomas: European society of endocrinology clinical practice guideline in collaboration with the European network for the study of adrenal tumors. Eur. J. Endocrinol. 175(2), 1–34 (2016)CrossRef
4.
Zurück zum Zitat M. Terzolo, G. Osella, A. Alì, G. Borretta, F. Cesario, P. Paccotti, Subclinical Cushing’s syndrome in adrenal incidentaloma. Clin. Endocrinol. 48(1), 89–97 (1998)CrossRef M. Terzolo, G. Osella, A. Alì, G. Borretta, F. Cesario, P. Paccotti, Subclinical Cushing’s syndrome in adrenal incidentaloma. Clin. Endocrinol. 48(1), 89–97 (1998)CrossRef
5.
Zurück zum Zitat M. Zeiger, G.B. Thompson, Q.-Y. Duh, A.H. Hamrahian, P. Angelos, D. Elaraj, E. Fishman, The American association of clinical endocrinologists and American association of endocrine surgeons medical guidelines for the management of adrenal incidentalomas. Endocr. Pract. 15(1), 1–20 (2009)CrossRefPubMed M. Zeiger, G.B. Thompson, Q.-Y. Duh, A.H. Hamrahian, P. Angelos, D. Elaraj, E. Fishman, The American association of clinical endocrinologists and American association of endocrine surgeons medical guidelines for the management of adrenal incidentalomas. Endocr. Pract. 15(1), 1–20 (2009)CrossRefPubMed
6.
Zurück zum Zitat M. Debono, J. Newell-Price, Subclinical hypercortisolism in adrenal incidentaloma. Curr. Opin. Endocrinol. Diabetes. Obes. 22(3), 185–192 (2015) M. Debono, J. Newell-Price, Subclinical hypercortisolism in adrenal incidentaloma. Curr. Opin. Endocrinol. Diabetes. Obes. 22(3), 185–192 (2015)
7.
Zurück zum Zitat M. Debono, M. Bradburn, M. Bull, B. Harrison, R.J. Ross, J. Newell-Price, Cortisol as a marker for increased mortality in patients with incidental adrenocortical adenomas. J. Clin. Endocrinol. Metab. 99(12), 4462–4470 (2014)CrossRefPubMedPubMedCentral M. Debono, M. Bradburn, M. Bull, B. Harrison, R.J. Ross, J. Newell-Price, Cortisol as a marker for increased mortality in patients with incidental adrenocortical adenomas. J. Clin. Endocrinol. Metab. 99(12), 4462–4470 (2014)CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat H. Falhammar, L. Frisen, A.L. Hirschberg, C. Norrby, C. Almqvist, A. Nordenskjold, A. Nordenstrom, Increased cardiovascular and metabolic morbidity in patients with 21-hydroxylase deficiency: a Swedish population-based national cohort study. J. Clin. Endocrinol. Metab. 100(9), 3520–3528 (2015)CrossRefPubMed H. Falhammar, L. Frisen, A.L. Hirschberg, C. Norrby, C. Almqvist, A. Nordenskjold, A. Nordenstrom, Increased cardiovascular and metabolic morbidity in patients with 21-hydroxylase deficiency: a Swedish population-based national cohort study. J. Clin. Endocrinol. Metab. 100(9), 3520–3528 (2015)CrossRefPubMed
9.
Zurück zum Zitat J. Patrova, I. Jarocka, H. Wahrenberg, H. Falhammar, Clinical outcomes in adrenal incidentaloma: experience from one center. Endocr. Pract. 21(8), 870–877 (2015)CrossRefPubMed J. Patrova, I. Jarocka, H. Wahrenberg, H. Falhammar, Clinical outcomes in adrenal incidentaloma: experience from one center. Endocr. Pract. 21(8), 870–877 (2015)CrossRefPubMed
10.
Zurück zum Zitat L. Barzon, M. Boscaro, Diagnosis and management of adrenal incidentalomas. J. Urol. 163(2), 398–407 (2000)CrossRefPubMed L. Barzon, M. Boscaro, Diagnosis and management of adrenal incidentalomas. J. Urol. 163(2), 398–407 (2000)CrossRefPubMed
11.
Zurück zum Zitat B. Bülow, S. Jansson, C. Juhlin, L. Steen, M. Thorén, H. Wahrenberg, S. Valdemarsson, B. Wängberg, B. Ahrén, Adrenal incidentaloma-Follow up results from a Swedish prospective study. Eur. J. Endocrinol. 154(3), 419–423 (2006)CrossRefPubMed B. Bülow, S. Jansson, C. Juhlin, L. Steen, M. Thorén, H. Wahrenberg, S. Valdemarsson, B. Wängberg, B. Ahrén, Adrenal incidentaloma-Follow up results from a Swedish prospective study. Eur. J. Endocrinol. 154(3), 419–423 (2006)CrossRefPubMed
12.
Zurück zum Zitat H. Yeomans, J. Calissendorff, C. Volpe, H. Falhammar, B. Mannheimer, Limited value of long-term biochemical follow-up in patients with adrenal incidentalomas-a retrospective cohort study. BMC Endocr. Disord. 15(6), 1–6 (2015) H. Yeomans, J. Calissendorff, C. Volpe, H. Falhammar, B. Mannheimer, Limited value of long-term biochemical follow-up in patients with adrenal incidentalomas-a retrospective cohort study. BMC Endocr. Disord. 15(6), 1–6 (2015)
13.
Zurück zum Zitat L. Barzon, C. Scaroni, N. Sonino, F. Fallo, Risk factors and long-term follow-up of adrenal incidentalomas. J. Clin. Endocrinol. Metab. 84(2), 520–526 (1999)PubMed L. Barzon, C. Scaroni, N. Sonino, F. Fallo, Risk factors and long-term follow-up of adrenal incidentalomas. J. Clin. Endocrinol. Metab. 84(2), 520–526 (1999)PubMed
14.
Zurück zum Zitat L. Barzon, F. Fallo, N. Sonino, M. Boscaro, Development of overt Cushing’s syndrome in patients with adrenal incidentaloma. Eur. J. Endocrinol. 146, 61–66 (2002) L. Barzon, F. Fallo, N. Sonino, M. Boscaro, Development of overt Cushing’s syndrome in patients with adrenal incidentaloma. Eur. J. Endocrinol. 146, 61–66 (2002)
15.
Zurück zum Zitat R. Libè, C. Dall’Asta, L. Barbetta, A. Baccarelli, P. Beck-Peccoz, B. Ambrosi, Long-term follow-up study of patients with adrenal incidentalomas. Eur. J. Endocrinol. 147(4), 489–494 (2002)CrossRefPubMed R. Libè, C. Dall’Asta, L. Barbetta, A. Baccarelli, P. Beck-Peccoz, B. Ambrosi, Long-term follow-up study of patients with adrenal incidentalomas. Eur. J. Endocrinol. 147(4), 489–494 (2002)CrossRefPubMed
16.
Zurück zum Zitat G. Di Dalmazi, V. Vicennati, S. Garelli, E. Casadio, E. Rinaldi, E. Giampalma, C. Mosconi, R. Golfieri, A. Paccapelo, U. Pagotto, R. Pasquali, Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing’s syndrome: a 15-year retrospective study. Lancet Diabetes Endocrinol. 2(5), 396–405 (2014)CrossRefPubMed G. Di Dalmazi, V. Vicennati, S. Garelli, E. Casadio, E. Rinaldi, E. Giampalma, C. Mosconi, R. Golfieri, A. Paccapelo, U. Pagotto, R. Pasquali, Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing’s syndrome: a 15-year retrospective study. Lancet Diabetes Endocrinol. 2(5), 396–405 (2014)CrossRefPubMed
17.
Zurück zum Zitat H.C. Abercrombie, J. Giese-Davis, S. Sephton, E.S. Epel, J.M. Turner-Cobb, M. Spiegel, Flattened cortisol rhythms in metastatic breast cancer patients. Psychoneuroendocrinology 29(8), 1082–1092 (2004)CrossRefPubMed H.C. Abercrombie, J. Giese-Davis, S. Sephton, E.S. Epel, J.M. Turner-Cobb, M. Spiegel, Flattened cortisol rhythms in metastatic breast cancer patients. Psychoneuroendocrinology 29(8), 1082–1092 (2004)CrossRefPubMed
18.
Zurück zum Zitat S.E. Sephton, F.S. Dhabhar, A.S. Keuroghlian, J. Giese-Davis, B.S. McEwen, A.C. Ionan, D. Spiegel, Depression, cortisol, and suppressed cell-mediated immunity in metastatic breast cancer. Brain Behav. Immun. 23(8), 1148–1155 (2009)CrossRefPubMed S.E. Sephton, F.S. Dhabhar, A.S. Keuroghlian, J. Giese-Davis, B.S. McEwen, A.C. Ionan, D. Spiegel, Depression, cortisol, and suppressed cell-mediated immunity in metastatic breast cancer. Brain Behav. Immun. 23(8), 1148–1155 (2009)CrossRefPubMed
19.
Zurück zum Zitat E. Filipski, V.M. King, X. Li, T.G. Granda, M.-C. Mormont, X. Liu, B. Claustrat, M.H. Hastings, F. Lévi, Host circadian clock as a control point in tumor progression. J. Natl Cancer Inst. 94(9), 690–697 (2002)CrossRefPubMed E. Filipski, V.M. King, X. Li, T.G. Granda, M.-C. Mormont, X. Liu, B. Claustrat, M.H. Hastings, F. Lévi, Host circadian clock as a control point in tumor progression. J. Natl Cancer Inst. 94(9), 690–697 (2002)CrossRefPubMed
20.
Zurück zum Zitat R.M. Sapolsky, T.M. Donnelly, Vulnerability to Stress-Induced Tumor Growth Increases with Age in Rats: role of glucocorticoids. Endocrinology 117(2), 662–666 (1985) R.M. Sapolsky, T.M. Donnelly, Vulnerability to Stress-Induced Tumor Growth Increases with Age in Rats: role of glucocorticoids. Endocrinology 117(2), 662–666 (1985)
21.
Zurück zum Zitat T.J. Moran, S. Gray, C.A. Mikosz, S.D. Conzen, The glucocorticoid receptor mediates a survival signal in human mammary epithelial cells. Cancer Res. 60(4), 867–872 (2000)PubMed T.J. Moran, S. Gray, C.A. Mikosz, S.D. Conzen, The glucocorticoid receptor mediates a survival signal in human mammary epithelial cells. Cancer Res. 60(4), 867–872 (2000)PubMed
22.
Zurück zum Zitat T.M. Rae, S.H. Hillier, Steroid signalling in the ovarian surface epithelium. Trends Endocrinol. Metab. 16(7), 327–333 (2005)CrossRefPubMed T.M. Rae, S.H. Hillier, Steroid signalling in the ovarian surface epithelium. Trends Endocrinol. Metab. 16(7), 327–333 (2005)CrossRefPubMed
23.
Zurück zum Zitat G. Di Dalmazi, V. Vicennati, E. Rinaldi, A.M. Morselli-Labate, E. Giampalma, C. Mosconi, U. Pagotto, R. Pasquali, Progressively increased patterns of subclinical cortisol hypersecretion in adrenal incidentalomas differently predict major metabolic and cardiovascular outcomes: a large cross-sectional study. Eur. J. Endocrinol. 166(4), 669–677 (2012)CrossRefPubMed G. Di Dalmazi, V. Vicennati, E. Rinaldi, A.M. Morselli-Labate, E. Giampalma, C. Mosconi, U. Pagotto, R. Pasquali, Progressively increased patterns of subclinical cortisol hypersecretion in adrenal incidentalomas differently predict major metabolic and cardiovascular outcomes: a large cross-sectional study. Eur. J. Endocrinol. 166(4), 669–677 (2012)CrossRefPubMed
24.
Zurück zum Zitat R. Rossi, L. Tauchmanova, A. Luciano, M.D.I. Martino, C. Battista, O. Molecolare, Subclinical cushing’s syndrome in patients with adrenal incidentaloma: clinical and biochemical features. J. Clin. Endocrinol. Metabol. 85(4), 1440–1448 (2000) R. Rossi, L. Tauchmanova, A. Luciano, M.D.I. Martino, C. Battista, O. Molecolare, Subclinical cushing’s syndrome in patients with adrenal incidentaloma: clinical and biochemical features. J. Clin. Endocrinol. Metabol. 85(4), 1440–1448 (2000)
25.
Zurück zum Zitat G. Di Dalmazi, Update on the risks of benign adrenocortical incidentalomas. Curr. Opin. Endocrinol. Diabetes Obes. 193–199, (2017) G. Di Dalmazi, Update on the risks of benign adrenocortical incidentalomas. Curr. Opin. Endocrinol. Diabetes Obes. 193–199, (2017)
26.
Zurück zum Zitat D. Lopez, M.A. Luque-Fernandez, A. Steele, G.K. Adler, A. Turchin, A. Vaidya, ‘Nonfunctional’ adrenal tumors and the risk for incident diabetes and cardiovascular outcomes. Ann. Intern. Med. 165(8), 533–542 (2016) D. Lopez, M.A. Luque-Fernandez, A. Steele, G.K. Adler, A. Turchin, A. Vaidya, ‘Nonfunctional’ adrenal tumors and the risk for incident diabetes and cardiovascular outcomes. Ann. Intern. Med. 165(8), 533–542 (2016)
27.
Zurück zum Zitat H. Olsen, E. Nordenström, A. Bergenfelz, U. Nyman, S. Valdemarsson, E. Palmqvist, Subclinical hypercortisolism and CT appearance in adrenal incidentalomas: a multicenter study from Southern Sweden. Endocrine 42(1), 164–172 (2012)CrossRefPubMed H. Olsen, E. Nordenström, A. Bergenfelz, U. Nyman, S. Valdemarsson, E. Palmqvist, Subclinical hypercortisolism and CT appearance in adrenal incidentalomas: a multicenter study from Southern Sweden. Endocrine 42(1), 164–172 (2012)CrossRefPubMed
28.
Zurück zum Zitat A.S. Mihailidou, T.Y.L. Le, M. Mardini, Y.W. Funder, Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension 54(6), 1306–1312 (2009)CrossRefPubMed A.S. Mihailidou, T.Y.L. Le, M. Mardini, Y.W. Funder, Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension 54(6), 1306–1312 (2009)CrossRefPubMed
29.
Zurück zum Zitat M. De Leo, R. Pivonello, R.S. Auriemma, A. Cozzolino, P. Vitale, C. Simeoli, M.C. De Martino, G. Lombardi, A. Colao, Cardiovascular disease in Cushing’s syndrome: heart versus vasculature. Neuroendocrinology 92(1), 50–54 (2010)CrossRefPubMed M. De Leo, R. Pivonello, R.S. Auriemma, A. Cozzolino, P. Vitale, C. Simeoli, M.C. De Martino, G. Lombardi, A. Colao, Cardiovascular disease in Cushing’s syndrome: heart versus vasculature. Neuroendocrinology 92(1), 50–54 (2010)CrossRefPubMed
30.
Zurück zum Zitat A. Toniato, I. Merante-Boschin, G. Opocher, M.R. Pelizzo, F. Schiavi, E. Ballotta, Surgical versus conservative management for subclinical Cushing syndrome in adrenal incidentalomas: a prospective randomized study. Ann. Surg. 249(3), 388–391 (2009)CrossRefPubMed A. Toniato, I. Merante-Boschin, G. Opocher, M.R. Pelizzo, F. Schiavi, E. Ballotta, Surgical versus conservative management for subclinical Cushing syndrome in adrenal incidentalomas: a prospective randomized study. Ann. Surg. 249(3), 388–391 (2009)CrossRefPubMed
31.
Zurück zum Zitat I.I. Androulakis, G.A. Kaltsas, G.E. Kollias, A.C. Markou, A.K. Gouli, D.A. Thomas, K.I. Alexandraki, C.M. Papamichael, D.J. Hadjidakis, G.P. Piaditis, Patients with apparently nonfunctioning adrenal incidentalomas may be at increased cardiovascular risk due to excessive cortisol secretion. J. Clin. Endocrinol. Metab. 99(8), 2754–2762 (2014)CrossRefPubMed I.I. Androulakis, G.A. Kaltsas, G.E. Kollias, A.C. Markou, A.K. Gouli, D.A. Thomas, K.I. Alexandraki, C.M. Papamichael, D.J. Hadjidakis, G.P. Piaditis, Patients with apparently nonfunctioning adrenal incidentalomas may be at increased cardiovascular risk due to excessive cortisol secretion. J. Clin. Endocrinol. Metab. 99(8), 2754–2762 (2014)CrossRefPubMed
Metadaten
Titel
Increased mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: a 13-year retrospective study from one center
verfasst von
Jekaterina Patrova
Magnus Kjellman
Hans Wahrenberg
Henrik Falhammar
Publikationsdatum
08.09.2017
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2017
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-017-1400-8

Weitere Artikel der Ausgabe 2/2017

Endocrine 2/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.